Electrochemical and enzymatic synthesis of oxidative drug metabolites for metabolism studies Gül, Turan
Microbial flavoprotein monooxygenases as mimics of mammalian flavin-containing monooxygenases for the enantioselective preparation of drug metabolites
ammalian flavin-containing monooxygenases are difficult to obtain and study while they play a major role in detoxifying various xenobiotics. In order to provide alternative biocatalytic tools to generate FMO-derived drug metabolites, a collection of microbial flavoprotein monooxygenases, sequence-related to human flavin-containing monooxygenases (FMOs), was tested for their ability to oxidize a set of xenobiotic compounds. For all tested xenobiotics (nicotine, lidocaine, 3-(methylthio)aniline, albendazole, and fenbendazole), one or more monooxygenases were identified capable of converting the target compound. Chiral LC-MS/MS analyses of the conversions of 3-(methylthio)aniline, albendazole and fenbendazole revealed that the respective sulfoxides are formed in good to excellent enantiomeric excess by several of the tested monooxygenases. Intriguingly, depending on the chosen microbial monooxygenase, either the (R)-or (S)-sulfoxide was formed. For example, when using a monooxygenase from Rhodococcus jostii the (S)-sulfoxide of albendazole (ricobendazole) was obtained with an e.e. of 95%, while a fungal monooxygenase yielded the respective (R)-sulfoxide in 57% e.e. For nicotine and lidocaine, monooxygenases could be identified that convert the amines into their respective N-oxides. This study shows that recombinantly expressed microbial monooxygenases represent a valuable toolbox of mammalian FMO mimics that can be exploited for the production of FMO-associated xenobiotic metabolites. 
Introduction
Metabolism of xenobiotics in humans and other mammals often starts with oxidation of the target molecule. Most of the Phase I metabolism reactions are catalyzed by cytochrome P450 monooxygenases (CYP450s) [1] . However, apart from CYP450s, recent studies have shown that the so-called flavin-containing monooxygenases (FMOs) also play a crucial role in the biotransformation of a large variety of xenobiotics, including pharmaceuticals and natural products. Mammals typically employ several FMO isoforms. The human proteome contains 5 isoforms, FMO1-FMO5, all of which have their typical tissue-dependent expression patterns and roles in metabolism [2] . FMOs have been shown to be involved in the oxygenation of heteroatom-containing compounds, such as amines and sulfides [2] [3] [4] . Different from CYP450s, which contain a heme cofactor, FMOs utilize a flavin cofactor for oxidations which also translates into a different oxidative mechanism. Furthermore, to discriminate between metabolism by human FMOs or CYP50s, often differences in stability and specific inhibitors can be used [5] . FMO enzymes require NADPH for reducing the FAD flavin cofactor. The reduced flavin subsequently reacts with molecular oxygen resulting in the formation of a reactive 4ahydroperoxyflavin. This reactive flavin intermediate is able to perform a variety of oxygenation reactions, for example sulfoxidations and N-hydroxylations (see [1, 2, 4, [6] [7] [8] [9] for mechanistic details).
While it has been established that human FMOs are essential in oxidizing a variety of xenobiotics, biochemical and metabolic studies on these enzymes are hampered by their poor availability. Human FMOs (hFMOs) and their mammalian orthologs are typically membrane associated and often thermolable which appear to be the major reasons for their problematic isolation from tissue [10, 11] and inefficient recombinant production. While human FMOs can be studied using microsomal preparations and some human FMOs were expressed as functional enzymes in heterologous hosts [12] [13] [14] [15] , these enzyme preparations involve costly and cumbersome isolation procedures, and often suffer from low activity and stability [2, 16] . Sequence comparison studies have revealed that FMOs are part of a large family of monooxygenases, the so-called Class B flavoprotein monooxygenases [17] . Intriguingly, many bacteria and fungi contain sequence-related Class B flavincontaining monooxygenases [18] that are typically involved in catalyzing Baeyer-Villiger oxidations forming a subfamily of Baeyer-Villiger monooxygenases (BVMOs). Biocatalytic studies on these microbial monooxygenases confirmed that they employ the same catalytic mechanism as FMOs [19] and, interestingly, are also able to catalyze oxygenations of heteroatom containing compounds. In contrast to hFMOs, many microbial BVMOs are soluble enzymes and can be easily produced in recombinant form [20] .
Inspired by the observation that microbial BVMOs are sequence-related to human FMOs and exhibit similar activities, we set out to explore their use as mammalian FMO mimics. By testing a panel of xenobiotic compounds, including drug molecules, with a collection of microbial BVMOs, we discovered that these biocatalysts may serve as tools to prepare metabolites. By choosing the proper monooxygenase, all tested xenobiotics (nicotine, lidocaine, 3-(methylthio)aniline, albendazole, and fenbendazole, see Figure 1 ) could be converted. Chiral LC-MS/MS analysis showed that sulfides were converted to the corresponding sulfoxides with excellent and complementary enantioselectivities. This study reveals that recombinant microbial BVMOs, which are relatively easy to produce and robust as biocatalysts, represent attractive alternatives to mammalian FMOs for the preparation of FMO-related metabolites. 
Materials and Methods

Materials
3-(Methylthio)aniline, albendazole, ricobendazole (racemic albendazole sulfoxide), fenbendazole, lidocaine, nicotine, 1,4-dioxane and Tris were purchased from Sigma-Aldrich (Zwijndrecht, The Netherlands). Acetaminophen was purchased from Fluka, ultra-pure HPLC grade acetonitrile and HPLC grade methanol were purchased from Biosolve (Valkenswaard, The Netherlands). Catalase was purchased from Fluka while phosphite dehydrogenase was prepared using an established protocol [21] . Ultrapure water was obtained from a Milli-Q Advantage A10 Water
Purification system (Millipore Corp., Billerica, MA, USA). Oasis HLB 30 mg solid phase extraction (SPE) cartridges were purchased from Waters (Manchester, UK).
Recombinant expression of BVMOs and preparation of cell extracts
The enzymes were overexpressed in Escherichia coli using previously established conditions and protocols. CHMOAc, PAMOM446G and BVMORj24 were expressed using the pCRE2 expression vector [22] , yielding the enzyme fused to His-tagged phosphite dehydrogenase which facilitates cofactor regeneration. His-tagged PAMO and Strep-tagged FMORjE were expressed as described previously [23] while for expressing BVMOMt1, a pET_SUMO vector was used. Precultures were grown overnight at 37 °C with shaking (180 rpm) in lysogeny broth (LB) medium containing ampicillin (50 μg/mL). The exception was BVMOMt1 for which cells were grown in the presence of kanamycin (100 μg/mL). Flasks containing 200 mL TB medium with the respective antibiotic were inoculated 1:100 (v/v) using the preculture and grown for another 4 h at 30 °C. After that, each flask was supplemented with inducer:
1.0 mM isopropyl β-D-thiogalactopyranoside (IPTG) for BVMOMt1, and 0.02% arabinose for PAMO, PAMOM446G, and CHMOAc, and 0.002 % arabinose for the remaining enzymes. After 48 h of growth at 24 °C with shaking (130 rpm) cells were harvested by centrifugation at 4 °C, 17,000 g and resuspended in 50 mM Tris buffer pH 8. Cells were diluted to an OD600 of 212 for TB samples and an OD600 of 98 for LB samples. Subsequently, the cells were disrupted by sonication for 90 s using 2 s sonication pulses and 2 s breaks, while on ice. The prepared cell extracts were supplemented with glycerol (15%), aliquoted (100 μL in Eppendorf tubes), frozen in liquid nitrogen, and stored at -80 °C.
As negative control E. coli cells were grown without expression plasmid and used for the preparation of cell extract as described above. Overexpression of the enzymes was confirmed with SDS-PAGE by analyzing OD-normalized samples from bacterial cultures. Negative control experiments were performed by incubating substrates with cell extracts that did not contain any expressed monooxygenase. All the conversions were performed in duplicate. After 135 min of incubation at room temperature, a 100 μL sample was taken and proteins were precipitated by 71 adding 300 μL acetonitrile containing 0.2 % formic acid. Samples were vortexed for 30 s and centrifuged at 13000 rpm for 6.5 min. After centrifugation, 200 μL of the supernatants was evaporated to dryness under nitrogen prior to solid phase extraction (SPE). SPE was performed on Oasis HLB 30 mg cartridges that were wetted with acetonitrile and equilibrated with H2O/acetonitrile (95:5). Dried samples were dissolved in 200 μL water and loaded onto the cartridge. Water (3 x 250 μL) was used to wash the cartridges and the final elution was performed with acetonitrile (4 x 250 μL). For the LC-MS/MS analysis, samples were 10x diluted in water containing 10 PM acetaminophen, as an internal standard for LC-MS/MS signal normalization.
Monooxygenase-catalyzed conversions
Chiral LC-MS/MS in the Selected Reaction Monitoring (SRM) mode
LC-MS/MS analyses in the SRM mode were carried out on an HPLC system with an Accela Autosampler and a Surveyor Pump coupled to a TSQ Quantum AM triple quadrupole mass spectrometer (Thermo Finnigan, San José, CA) with an ESI interface in the positive mode (see Tables   1 and 2 The LC-MS/MS analysis of lidocaine and its N-oxide was performed by reversed-phase LC applying a linear gradient starting from 5% to 95% solvent B in solvent A over 11 min which was held for 1 min. Solvent B was decreased rapidly to 5% in 20 s and the column re-equilibrated at 5% solvent B for 4 min. The LC-MS/MS analysis of nicotine and its N-oxide was performed by HILIC applying a linear gradient starting from 10% to 90% solvent E in solvent D (acetonitrile) over 8 min which was held for 2 min. Solvent E was decreased rapidly to 10% in 20 s and finally the column re-equilibrated at 10% solvent E for 3 min. Acetaminophen was used as internal standard to normalize the peak areas across LC-MS/MS runs.
Circular Dichroism
In order to assign the absolute configuration of the products, samples were analyzed by CD spectroscopy. Samples were purified with SPE, dried by evaporation of acetonitrile, and dissolved in methanol to a nominal concentration of 0.75 mM. For CD analysis samples were further diluted 4 times in methanol. CD spectra were recorded on a J-810 spectropolarimeter (JASCO, Tokyo, Japan) using a 1 mm quartz cell cuvette and scanning from 200 to 350 nm at 25 °C; methanol was used as a blank. Table 1 . Parameters for the MS analysis of the different substrates and their conversion products. Scan time, Q1 peak width and skimmer offset were set to 1 s, 0.70 amu FWHM and 0, respectively. Albendazole  3000  30  15  300  90  50-400   fenbendazole  3000  40  15  350  90  50-500   lidocaine  3500  40  20  350  90  50-300   nicotine  2500  60  15  350  80  50-250  Table 2 . SRM transitions and corresponding collision energies for the substrates and their oxidation products. All SRM measurements were performed with a dwell time of 100 ms and Q1 and Q3 peak widths of 0.70 amu FWHM. 1 mTorr collision gas pressure was used for all compounds except for nicotine and its N-oxide products (1.5 mTorr). 
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Compounds
Conversion of the sulfide 3-methyl(thio)aniline
We selected seven microbial flavoprotein monooxygenases originating from three different microorganisms. Besides three well-studied BVMOs, phenylacetone monooxygenase (PAMO) from
Thermobifida fusca [23] , the Met446Gly PAMO mutant (PAMOM446G) [24] and cyclohexanone monooxygenase from Acinetobacter calcoaceticus (CHMOAc) [22] , two recently discovered BVMOs from Rhodoccocus jostii (BVMORj4 and BVMORj24) [25] and a BVMO from the fungus Myceliophthora thermophila (BVMOMt1) were included in this study. Furthermore, we also included a representative of a newly discovered distinct subfamily of microbial monooxygenases, the so-called Type II FMOs, that share characteristics of both BVMOs and FMOs: FMORjE from R. jostii [25] . All studied monooxygenases belong to the Class B flavoprotein monooxygenases and, hence, are distantly related to mammalian FMOs as evidenced by significant sequence identities (20-40 %) and highly conserved sequence motifs [4] . Also the obtained crystal structures of a bacterial FMO and several BVMOs have confirmed that Class B flavoprotein monooxygenases share structural and mechanistic features [8, 26] . CHMOAc and PAMO display complementary and broad substrate acceptance profiles [19] , while the other monooxygenases have been hardly explored for their substrate scope. Therefore, we anticipated that by studying such a large panel of different microbial monooxygenases, several targeted compounds could be converted by one or more monooxygenases. PAMO and PAMO mutants have been shown to be able to efficiently convert aromatic sulfides [27] .
Human FMOs are also known for their ability to perform sulfoxidations of aromatic sulfides or thioureas [2, 28] . Depending on the type of sulfide and FMO isoform, various enantioselectivities by mammalian FMOs have been described [29] [30] [31] . Figure 7 ). This indicates that with the current approach 4-5 mg of enantiopure sulfoxide metabolite is produced in 1 h using a cell extract from a 1 L culture. 
Conversion of the thioether drugs, albendazole and fenbendazole
Two drugs that are commonly used to treat worm infestations in mammals, albendazole and fenbendazole, are known to be converted in an enantioselective manner into their sulfoxides by mammalian FMOs [31] . The yields of albendazole sulfoxide were determined with standard addition and reached 55% for BVMORj24 and 25% for BVMOMt1 (Figure 8 ). This corresponds to 1-2 mg/h and per L of bacterial culture. Less than 1% of the sulfone product was formed by BVMORj24, BVMOMt1 and CHMOAc upon conversion. No other side products were detected. Chiral LC-MS/MS in the SRM mode showed that conversion of fenbendazole by BVMOMt1 yields (S)-fenbendazole sulfoxide in 96% e.e. (Figure 5 ). 
Conversion of the amines, lidocaine and nicotine
Lidocaine and nicotine contain a regular and a cyclic tertiary amine group, respectively. Lidocaine is a widely-used local anesthetic while nicotine is a plant alkaloid which acts as a stimulant. Both drugs are known to be oxidized by mammalian FMOs into their corresponding N-oxides. LC-MS/MS analysis showed that significant conversion of lidocaine into the N-oxide is performed by BVMORj24, while nicotine is converted by CHMOAc ( Figure 6 ). With the applied conditions, the degree of conversion for both substrates was rather low, below 10%. For lidocaine no other products (specifically the Cytochrome P450-catalyzed N-dealkylation or aromatic hydroxylation products) were observed in significant amounts. The N-oxide of lidocaine can be distinguished from other monooxygenation products by its specific SRM transition (m/z 251/130).
Additionally, its retention time was confirmed using a chemically oxidized lidocaine N-oxide standard.
LC-MS/MS analysis of the nicotine conversion samples showed two N-oxidation products which could be assigned on the basis of their fragmentation patterns; the SRM transition of m/z 179/117 is unique for nicotine-1`-N-oxide (oxidation of nitrogen on the pyrrolidine ring) and the m/z 179/148 transition is unique for nicotine-1-N-oxide (oxidation of nitrogen on the pyridine ring) [35, 36] . The nicotine-1`-N-oxide product was the major N-oxide formed by CHMOAc. The low amount of nicotine-1-N-oxide was similar to the amount formed in the control reaction.
Quantification of product yields with standard addition method
3-methyl(thio)aniline
Since a 3-(methylthio)aniline sulfoxide standard was not available, we measured the concentration of 3-(methylthio)aniline remaining after the 135 min conversion reaction. During the conversion reaction 3 mM 3-(methylthio)aniline was used. In the extraction step, the sample was diluted 4 times (to a nominal concentration of 750 PM) and in the SPE purification step it was diluted a further 20 times. For the LC-MS/MS quantification, control (extract with no monooxygenase expressed), BVMORj24 and BVMOMt1 samples were diluted 10 times more, and used as unknowns in the standard addition method (see Table 3 ). All the quantification experiments were duplicated.
The control sample was used to determine the 3-(methylthio)aniline concentration after extraction and SPE cleanup, but without conversion. Samples were analyzed with LC-MS/MS and peak areas were plotted (Figure 7 ). According to the standard addition curve the concentration of unknown (control) was 3.2 PM. The remaining 3-(methylthio)aniline concentrations after 135 min incubation in BVMORj24 and BVMOC1a samples were found to be 0.9 PM and 0.1 PM (Figure 7 ). Based on these concentrations and that of the control, the consumption of 3-(methylthio)aniline after 135 min incubation was calculated to be roughly 72% for BVMORj24 and 97% for BVMOMt1, without correcting for recovery or sample instability during storage. Table 3 . Standard addition method used for quantification of 3-(methylthio)aniline, albendazole and albendazole sulfoxide in enzymatic conversion. All dilution series had a total volume of 1 mL. 
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Albendazole sulfoxide
BVMORj24 and BVMOMt1 samples, which showed the highest of albendazole sulfoxide peaks in LC-MS/MS were used for quantification. The same extraction, SPE purification and dilution steps were followed for albendazole as stated for 3-(methylthio)aniline(see Table 3 ).
To a control extract 1 mM of ricobendazole (racemic albendazole sulfoxide) was added and used as a control (Figure 8) to correct for the loss during the extraction and SPE purification steps. The concentration determined to be 2.0 PM. The albendazole sulfoxide product concentrations were calculated to be 1.1 PM for BVMORj24 and 0.5 PM for BVMOMt1. The estimated product yield of albendazole sulfoxide is therefore 55% for BVMORj24 and 25% for BVMOMt1 ( Figure 8 ). 
Discussion
Human FMOs and other mammalian FMOs play a crucial role in degrading a wide range of xenobiotics, including many drugs. While they are known for their chemo-and enantioselective oxidations, mammalian FMOs are notoriously difficult to obtain or to use as isolated biocatalysts. To provide an alternative for the biocatalytic production of FMO-derived metabolites, we explored the use of the microbial Class B flavoprotein monooxygenases which are all sequence-related to FMOs.
Besides sequence similarities, members of the Class B flavoprotein monooxygenases all share a similar structural fold. They are composed of FAD-binding domain with a tightly bound FAD as a prosthetic group and a NADPH binding domain which binds NADPH as coenzyme during catalysis [4] . In addition, kinetic and mechanistic studies on FMOs and BVMOs have revealed that these flavoprotein monooxygenases also share a common catalytic mechanism. This is also reflected in the type of oxygenations reactions that are catalyzed by members of both monooxygenase groups: they overlap and include N-oxygenations, sulfoxidations and Baeyer-Villiger oxidations [37] . The catalytic cycle starts with binding of the reduced coenzyme NADPH which results in reduction of the flavin cofactor.
Through a subsequent fast reaction with molecular oxygen, the peroxyflavin intermediate is formed that is key to catalyze substrate oxygenation [19, 38] . The reactive peroxyflavin is stabilized through Another advantage of this approach is the fact that in the last decade a large number of recombinant microbial flavoprotein monooxygenases have become available. For example, we have generated an in-house library of >30 different microbial flavoprotein monooxygenases [23, 39] . For our study we decided to explore a set of seven monooxygenases that are known to display dissimilar substrate acceptance and oxygenation selectivity profiles.
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Five different xenobiotics (3-(methylthio)aniline, albendazole, fenbendazole, lidocaine and nicotine) were chosen to examine enantio-, region-and chemoselective oxygenation by using a panel of seven different recombinant microbial flavoprotein monooxygenases. Chiral LC-MS/MS in the SRM mode was instrumental in establishing activity and selectivity of each enzyme towards each test compound. The enzymes that were found to be able to convert albendazole and fenbendazole formed the corresponding sulfoxides with very good enantiomeric excess. Both enantiomers of albendazole sulfoxide were produced in enantiomeric excess (CHMOAc and BVMOMt1 for the (R)-sulfoxide and BVMORj24 for the (S)-sulfoxide). Previously, it has been shown that mammalian FMOs have a preference for forming (R)-albendazole sulfoxide from albendazole [30, 31] . For fenbendazole, only one active enzyme (BVMOMt1) was identified which preferentially forms the (S)-sulfoxide.
Fenbendazole has been shown to be converted into the (R)-sulfoxide by mammalian FMOs with significant enantiomeric excess [30] . The observation that only one out of seven enzymes was active on fenbendazole may reflect the fact that fenbendazole differs from albendazole in having a phenyl moiety replacing a propyl moiety making it more bulky, sterically hindering oxidation of the thioether.
It is worth mentioning that, except for the formation of low amounts of sulfones, no other oxidation products were formed upon conversion of the tested thioethers which demonstrates that the monooxygenases are chemo-, regio-and enantioselective. Monooxygenases that form the N-oxides of nicotine (CHMOAc) and lidocaine (BVMORj24) were also identified. In the literature it was reported that human FMO3 is responsible for selective formation of nicotine-1`-N-oxide [16] , which was also the major N-oxide formed by CHMOAc. This shows that the microbial monooxygenases can also be used for chemo-and regioselective N-oxidations of xenobiotics.
Our study illustrates that sequence-related microbial monooxygenases can be used for the production of FMO-related metabolites. As for mammalian FMOs [11, 16] , each tested oxidation was very specific and no side products were formed in considerable amounts. This makes them interesting biocatalysts for the production of pharmaceutically relevant drug metabolites.
